uniQure N.V.
QUREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, uniQure N.V. focuses on Biotechnology services and products. uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. With a market capitalization of $3.17B, it sits in mid-cap territory. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Market Cap
$3.17B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-14.93
EPS (TTM)
$-4.06
EPS (Fwd)
$-3.06
ROE
-157.6%
ROA
-15.7%
Cash
$810.3M
Total Debt
$552.2M
Free CF
-$77.6M
52W Change
154.6%
Annual Financials
Cash vs Debt
Where QURE stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, QURE finished 62.84% above its 150-day moving average ($29.39) and 70.14% above its 200-day moving average ($28.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QURE overbought or oversold?
At the September 2, 2026 close, QURE's RSI(14) was 59.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $810.3M in cash and $552.2M in debt, QURE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$77.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -157.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $106.5M (2022) to $16.1M (2025), a 85% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence uniQure N.V.'s trajectory.